OCULAR THERAPEUTIX, INC Cost of Revenue
OCULAR THERAPEUTIX, INC (OCUL) reported Cost of Revenue of $2.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC cost of goods and services sold for the quarter ending 2026-06-30 was $2.01M, a 3.45% increase year-over-year.
- OCULAR THERAPEUTIX, INC cost of goods and services sold for the quarter ending 2026-03-31 was $1.33M, a 5.31% increase year-over-year.
- OCULAR THERAPEUTIX, INC cost of goods and services sold for the quarter ending 2025-12-31 was $1.59M, a 29.59% increase year-over-year.
- OCULAR THERAPEUTIX, INC cost of goods and services sold for the quarter ending 2025-09-30 was $1.77M, a 13.65% increase year-over-year.
- OCULAR THERAPEUTIX, INC cost of goods and services sold for fiscal 2025 was $6.57M, a 16.85% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC cost of goods and services sold for fiscal 2024 was $5.63M, a 6.53% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC cost of goods and services sold for fiscal 2023 was $5.28M, a 16.32% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC cost of goods and services sold for fiscal 2022 was $4.54M, a 3.04% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.01M 10-Q · filed 2026-08-03 | $3.34M 10-Q · filed 2026-08-03 | $4.93M derived: sum of 3 quarters · filed 2026-08-03 | $6.71M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $1.33M 10-Q · filed 2026-05-05 | $2.92M derived: sum of 2 quarters · filed 2026-05-05 | $4.70M derived: sum of 3 quarters · filed 2026-05-05 | $6.64M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $3.37M derived: sum of 2 quarters · filed 2026-02-05 | $5.31M derived: sum of 3 quarters · filed 2026-08-03 | $6.57M 10-K · filed 2026-02-05 |
| 2025-09-30 | $1.77M 10-Q · filed 2025-11-04 | $3.72M derived: sum of 2 quarters · filed 2026-08-03 | $4.98M 10-Q · filed 2025-11-04 | $6.21M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $1.94M 10-Q · filed 2026-08-03 | $3.21M 10-Q · filed 2026-08-03 | $4.44M derived: sum of 3 quarters · filed 2026-08-03 | $6.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.26M 10-Q · filed 2026-05-05 | $2.49M derived: sum of 2 quarters · filed 2026-05-05 | $4.05M derived: sum of 3 quarters · filed 2026-05-05 | $5.56M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $2.79M derived: sum of 2 quarters · filed 2026-02-05 | $4.30M derived: sum of 3 quarters · filed 2026-02-05 | $5.63M 10-K · filed 2026-02-05 |
| 2024-09-30 | $1.56M 10-Q · filed 2025-11-04 | $3.07M derived: sum of 2 quarters · filed 2025-11-04 | $4.40M 10-Q · filed 2025-11-04 | $5.78M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-06-30 | $1.51M 10-Q · filed 2025-08-05 | $2.83M 10-Q · filed 2025-08-05 | $4.22M derived: sum of 3 quarters · filed 2026-02-05 | $5.60M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-03-31 | $1.33M 10-Q · filed 2025-05-05 | $2.71M derived: sum of 2 quarters · filed 2026-02-05 | $4.09M derived: sum of 3 quarters · filed 2026-02-05 | $5.39M derived: sum of 4 quarters · filed 2026-02-05 |
| 2023-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $2.76M derived: sum of 2 quarters · filed 2026-02-05 | $4.07M derived: sum of 3 quarters · filed 2026-02-05 | $5.28M 10-K · filed 2026-02-05 |
| 2023-09-30 | $1.38M 10-Q · filed 2024-11-14 | $2.68M derived: sum of 2 quarters · filed 2024-11-14 | $3.90M 10-Q · filed 2024-11-14 | $4.91M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.30M 10-Q · filed 2024-08-07 | $2.52M 10-Q · filed 2024-08-07 | $3.53M derived: sum of 3 quarters · filed 2025-03-03 | $4.60M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $1.21M 10-Q · filed 2024-05-07 | $2.23M derived: sum of 2 quarters · filed 2025-03-03 | $3.30M derived: sum of 3 quarters · filed 2025-03-03 | $4.45M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.08M derived: sum of 2 quarters · filed 2025-03-03 | $3.24M derived: sum of 3 quarters · filed 2025-03-03 | $4.54M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.07M 10-Q · filed 2023-11-07 | $2.23M derived: sum of 2 quarters · filed 2023-11-07 | $3.53M 10-Q · filed 2023-11-07 | $4.64M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $1.16M 10-Q · filed 2023-08-07 | $2.45M 10-Q · filed 2023-08-07 | $3.56M derived: sum of 3 quarters · filed 2024-03-11 | $4.87M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $1.30M 10-Q · filed 2023-05-08 | $2.41M derived: sum of 2 quarters · filed 2024-03-11 | $3.72M derived: sum of 3 quarters · filed 2024-03-11 | $4.81M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $2.42M derived: sum of 2 quarters · filed 2024-03-11 | $3.51M derived: sum of 3 quarters · filed 2024-03-11 | $4.41M 10-K · filed 2024-03-11 |
| 2021-09-30 | $1.31M 10-Q · filed 2022-11-07 | $2.41M derived: sum of 2 quarters · filed 2022-11-07 | $3.30M 10-Q · filed 2022-11-07 | $3.98M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $1.10M 10-Q · filed 2022-08-08 | $1.99M 10-Q · filed 2022-08-08 | $2.67M derived: sum of 3 quarters · filed 2023-03-06 | $3.12M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $892.00K 10-Q · filed 2022-05-09 | $1.57M derived: sum of 2 quarters · filed 2023-03-06 | $2.02M derived: sum of 3 quarters · filed 2023-03-06 | $2.16M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $680.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $1.13M derived: sum of 2 quarters · filed 2023-03-06 | $1.26M derived: sum of 3 quarters · filed 2023-03-06 | $2.08M 10-K · filed 2023-03-06 |
| 2020-09-30 | $450.00K 10-Q · filed 2021-11-08 | $584.00K derived: sum of 2 quarters · filed 2021-11-08 | $1.40M 10-Q · filed 2021-11-08 | $2.24M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $134.00K 10-Q · filed 2021-08-09 | $953.00K 10-Q · filed 2021-08-09 | $1.79M derived: sum of 3 quarters · filed 2022-02-28 | $2.60M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $819.00K 10-Q · filed 2021-05-05 | $1.66M derived: sum of 2 quarters · filed 2022-02-28 | $2.46M derived: sum of 3 quarters · filed 2022-02-28 | $3.02M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $839.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.65M derived: sum of 2 quarters · filed 2022-02-28 | $2.20M derived: sum of 3 quarters · filed 2022-02-28 | $2.33M 10-K · filed 2022-02-28 |
| 2019-09-30 | $806.00K 10-Q · filed 2020-11-05 | $1.36M derived: sum of 2 quarters · filed 2020-11-05 | $1.49M 10-Q · filed 2020-11-05 | $1.60M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $552.00K 10-Q · filed 2020-08-07 | $680.00K 10-Q · filed 2020-08-07 | $797.00K derived: sum of 3 quarters · filed 2020-08-07 | $912.00K derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $128.00K 10-Q · filed 2020-05-08 | $245.00K derived: sum of 2 quarters · filed 2020-05-08 | $360.00K derived: sum of 3 quarters · filed 2020-05-08 | $513.00K derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $232.00K derived: sum of 2 quarters · filed 2020-03-12 | $385.00K derived: sum of 3 quarters · filed 2020-03-12 | $465.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | $115.00K 10-Q · filed 2019-11-12 | $268.00K derived: sum of 2 quarters · filed 2019-11-12 | $348.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $153.00K 10-Q · filed 2019-08-07 | $233.00K 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $80.00K 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $457.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |